Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
Karah Herdman Parschauer, Executive Vice President and Chief Legal Officer at Ultragenyx Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:RARE), recently sold a significant portion of the company’s stock. On March 3, 2025, Parschauer sold 12,846 shares of Ultragenyx common stock at an average price of $42.10 per share, amounting to a total transaction value of approximately $540,816. The transaction comes as the $3.82 billion biotech company trades near $41, roughly 32% below its 52-week high of $60.37, with InvestingPro analysis indicating the stock is currently undervalued.
This sale was executed to cover required tax withholdings due to the vesting of restricted stock units (RSUs). Following this transaction, Parschauer retains direct ownership of 75,287 shares. Despite showing strong revenue growth of 29% in the last twelve months, Ultragenyx faces profitability challenges, with analysts not expecting positive earnings this year.
Earlier, on March 1, Parschauer acquired 18,443 shares of common stock at no cost, as previously granted performance stock units were converted upon certification of performance metrics. These transactions reflect ongoing adjustments in Parschauer’s holdings in the company. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro subscribers can access detailed financial health scores and additional ProTips.
In other recent news, Ultragenyx Pharmaceutical Inc. reported fourth-quarter 2024 earnings that exceeded expectations, driven by strong sales from its Crysvita, Dojolvi, and Evkeeza product lines. The company’s total revenue for the quarter was $164.9 million, surpassing estimates from Goldman Sachs and Visible Alpha. Ultragenyx has maintained its full-year 2025 revenue guidance between $640 million and $670 million. Analysts from Canaccord Genuity raised their price target to $136, maintaining a Buy rating due to the company’s robust performance and promising pipeline. Similarly, H.C. Wainwright and Goldman Sachs reiterated Buy ratings with price targets of $95 and $78, respectively.
The FDA has accepted the Biologics License Application for UX111, a gene therapy for Sanfilippo syndrome type A, with a PDUFA action date set for August 2025. This development is part of Ultragenyx’s strategy to achieve GAAP profitability by 2027. Cantor Fitzgerald also reaffirmed its Overweight rating, highlighting the progress of the DTX301 program for OTC deficiency and upcoming clinical readouts for setrusumab. These recent developments underscore Ultragenyx’s ongoing efforts to advance its pipeline and address unmet medical needs in rare diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.